IntelGenx Technologies (IGXT) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 11, 2022
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Entity Registrant Name	INTELGENX TECHNOLOGIES CORP.
Entity Central Index Key	0001098880
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		154,951,290
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Shell Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6420 Abrams
Entity Address, City or Town	Ville Saint Laurent
Entity Address, State or Province	QC
Entity Address, Postal Zip Code	H4S 1Y2
Entity Address, Country	CA
City Area Code	514
Local Phone Number	331-7440
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-31187
Entity Tax Identification Number	87-0638336

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current
Cash	$ 6,614	$ 3,945
Short-term investments	3,635	6,004
Accounts receivable	754	680
Prepaid expenses	132	105
Investment tax credits receivable	225	436
Security deposits	208	205
Inventory	88	62
Total current assets	11,656	11,437
Leasehold improvements and equipment, net	5,163	5,213
Security deposits	256	252
Operating lease right-of-use assets	961	1,003
Total assets	18,036	17,905
Current
Accounts payable and accrued liabilities	2,351	2,299
Current portion of operating lease liability	252	249
Current portion of finance lease liability	37	36
Deferred revenue	138	189
Convertible debentures	4,327	4,247
Total current liabilities	7,105	7,020
Long-term debt	5,500	2,500
Convertible notes	4,138	3,709
Operating lease liability	604	642
Finance lease liability	75	84
Deferred income tax liability	0	79
Total liabilities	17,422	14,034
Shareholders' equity
Capital stock, common shares, $0.00001 par value; 450,000,000 shares authorized; 154,651,289 shares issued and outstanding (2021: 154,571,289 common shares)	1	1
Additional paid-in capital	62,842	63,104
Accumulated deficit	(60,526)	(57,863)
Accumulated other comprehensive loss	(1,703)	(1,371)
Total shareholders' equity	614	3,871
Total liabilities and shareholders' equity	$ 18,036	$ 17,905

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value per share	$ 0.00001	$ 0.00001
Common stock, shares authorized	450,000,000	450,000,000
Common stock, shares, issued	154,651,289	154,571,289
Common stock, shares, outstanding	154,651,289	154,571,289

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity (Unaudited) - 3 months ended Mar. 31, 2022 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance at Dec. 31, 2021	$ 3,871	$ 1	$ 63,104	$ (57,863)	$ (1,371)
Beginning Balance (Shares) at Dec. 31, 2021		154,571,289
Modified retrospective adjustment upon adoption of ASU 2020-06	(302)		(325)	23
Other comprehensive income	(332)				(332)
Conversion of convertible debentures	31		31
Conversion of convertible debentures (in shares)		80,000
Stock-based compensation	32		32
Net loss for the period	(2,686)			(2,686)
Ending Balance at Mar. 31, 2022	$ 614	$ 1	$ 62,842	$ (60,526)	$ (1,703)
Ending Balance (Shares) at Mar. 31, 2022		154,651,289

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Operations [Abstract]
Revenues	$ 237	$ 286
Total Revenues	237	286
Expenses
Research and development expense	798	471
Manufacturing expenses	470	621
Selling, general and administrative expense	1,084	929
Depreciation of tangible assets	195	192
Total expenses	2,547	2,213
Operating loss	(2,310)	(1,927)
Interest income	1	0
Financing and interest expense	(377)	(334)
Net financing and interest expense	(376)	(334)
Net Loss	(2,686)	(2,261)
Other Comprehensive Loss
Foreign currency translation adjustment	17	(27)
Change in fair value	(349)	(9)
Total other comprehensive loss	(332)	(36)
Comprehensive loss	$ (3,018)	$ (2,297)
Basic and Diluted Weighted Average Number of Shares Outstanding	154,595,511	111,722,199
Basic and Diluted Loss Per Common Share	$ (0.02)	$ (0.02)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Funds (used) provided - Operating activities
Net loss	$ (2,686)	$ (2,261)
Depreciation of tangible assets	195	192
Stock-based compensation	32	31
Accretion expense	91	138
DSU expense	68	115
Lease non-cash expense	1	1
Total Adjustment	(2,299)	(1,784)
Changes in non-cash items related to operations:
Accounts receivable	(74)	(116)
Prepaid expenses	(27)	(4)
Investment tax credits receivable	211	(72)
Contract asset	0	354
Inventory	(26)	126
Security deposits	0	206
Accounts payable and accrued liabilities	(21)	(157)
Deferred revenues	(51)	(22)
Net change in non-cash items related to operations	12	315
Net cash used in operating activities	(2,287)	(1,469)
Financing activities
Finance lease payments	(9)	(6)
Issuance of loan	3,000	2,000
Repayment of long-term debt	0	(737)
Net cash provided by financing activities	2,991	1,257
Investing activities
Additions to leasehold improvements and equipment	(64)	(12)
Redemption of short-term investments	5,719	627
Acquisition of short-term investments	(3,700)	0
Net cash provided by investing activities	1,955	615
Increase in cash	2,659	403
Effect of foreign exchange on cash	10	(36)
Cash
Beginning of period	3,945	1,205
End of period	$ 6,614	$ 1,572

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	1. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature. These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2021. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. IntelGenx Technologies Corp. (and collectively with IntelGenx Corp., our wholly-owned Canadian subsidiary, "IntelGenx" or the "Company") prepares its consolidated financial statements in accordance with accounting principles generally accepted in the United States of America ("USA"). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The consolidated financial statements include the accounts of IntelGenx Technologies Corp. and IntelGenx Corp. On consolidation, all inter-entity transactions and balances have been eliminated. The financial statements are expressed in U.S. funds. Management has performed an evaluation of the Company's activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Significant Accounting Policies Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Product revenue The Company recognizes revenue from the sale of its products when the following conditions are met: delivery has occurred; the price is fixed or determinable; the collectability is reasonably assured and persuasive evidence of an arrangement exists Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment Computer equipment On the straight-line method - Leasehold improvements Manufacturing equipment Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred. Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured as the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. Adoption of accounting policies ASU 2020-06-Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity The FASB issued ASU 2020-06,1 which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU 2020-06") to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity's own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity's own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of AASU 2020-06 had a substantial impact on the Company's balance sheet. The August 2021 convertible notes (note 8) contained a beneficial conversion feature. Under the new requirements, the beneficial conversion feature no longer requires to be recognized separately and the convertible notes are treated as a single financial liability. As such, the most significant impact were the reversals of the beneficial conversion feature and the deferred income tax liability. The impact of the adoption of ASU 2020-06 on the balance sheet as at December 31, 2021 was: As reported December 31, 2021 Adoption of ASC 2020-06 Increase Balance January 1, 2022 Convertible notes $ 3,709 $ 388 $ 4,097 Deferred income tax liability 79 (79 ) - Total liabilities 14,034 309 14,343 Additional paid-in capital 63,104 (325 ) 62,779 Accumulated deficit (57,863 ) 23 (57,840 ) Total shareholders' equity 3,871 (309 ) 3,562 Total liabilities and shareholders' equity 17,905 - 17,905

Inventory

Inventory	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories [Text Block]	3. Inventory Inventory as at March 31, 2022 consisted of raw materials in the amount of $88 thousand (2021: $62 thousand).

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment [Text Block]	4. Leasehold Improvements and Equipment March 31, December 31, Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,951 $ 1,602 $ 3,349 $ 3,349 Laboratory and office equipment 1,528 1,131 397 382 Computer equipment 158 118 40 39 Leasehold improvements 3,489 2,112 1,377 1,443 $ 10,126 $ 4,963 $ 5,163 $ 5,213 From the balance of manufacturing equipment, an amount of $1,881 thousand (2021: $1,832 thousand) represents assets which are still under construction as at March 31, 2022 and are consequently not depreciated.

Bank Indebtedness

Bank Indebtedness	3 Months Ended
	Mar. 31, 2022
Bank Indebtedness [Abstract]
Bank Indebtedness [Text Block]	5. Bank Indebtedness The Company's credit facility is subject to review annually and consists of corporate credits cards of up to CAD$75 thousand ($60 thousand) and $60 thousand, and foreign exchange contracts limited to CAD$425 thousand ($340 thousand).

Loan Payable

Loan Payable	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Loan Payable [Text Block]	6. Loan Payable atai Life Sciences ("atai") has granted to the Company a secured loan in the amount of $2,000,000, bearing interest at 8%. An additional advance for $500,000 was also granted in May 2021. Together with the initial amount of $2,000,000, atai has granted a total amount of $2,500,000 to the Company. In September 2021, the Company entered into an amended and restated secured loan agreement with atai pursuant to which atai has made two additional term loans available to the Company for $3,000,000 each, which will mature on January 5, 2024. The first loan was received on January 7, 2022 and the second loan will be made available on January 6, 2023, subject to the satisfaction of customary conditions. The Loan Agreement also extends the maturity date for the current loans, in an aggregate amount of $2,500,000, to January 2024. The loan is guaranteed by the Company and secured by all present and future movable property, rights and assets of the Company, excluding any intellectual property or technology controlled or owned by the Company. The loan bears interest at 8%. The interest for the three-month period ended March 31, 2022 amounts to $91,000 (2021: $10,000) and is recorded in financing and interest expense. The components of the Company's debt are as follows: March 31, 2022 $ December 31, 2021 $ Loan payable to atai 5,500 2,500 Total debt 5,500 2,500 Less: current portion - - Total long-term debt 5,500 2,500

Convertible Debentures

Convertible Debentures	3 Months Ended
	Mar. 31, 2022
Convertible Debt [Abstract]
Convertible Debentures [Text Block]	7. Convertible Debentures On July 12, 2017, the Company closed its previously announced prospectus offering (the "Offering") of convertible unsecured subordinated debentures of the Corporation (the "Debentures") for gross aggregate proceeds of CAD$6,838,000 ($5,472,000). Pursuant to the Offering, the Corporation issued an aggregate principal amount of CAD$6,838,000 ($5,472,000) of Debentures at a price of CAD$1,000 ($800) per Debenture. The Debentures had a maturity date of June 30, 2020 and interest at annual rate of 8% payable semi-annually on the last day of June and December of each year, commencing on December 31, 2017. The interest may be paid in common shares at the option of the Corporation. The Debentures were convertible at the option of the holders at any time prior to the close of business on the earlier of June 30, 2020 and the business day immediately preceding the date specified by the Corporation for redemption of Debentures. The conversion price was CAD$1.35 ($1.08) (the "Conversion Price") per common share of the Corporation ("Share"), being a conversion rate of approximately 740 Shares per CAD$1,000 ($800) principal amount of Debentures, subject to adjustment in certain events. On August 8, 2017, the Company closed a second tranche of its prospectus Offering of convertible unsecured subordinated debentures of the Corporation for which a first closing took place on July 12, pursuant to which it had raised additional gross proceeds of CAD$762,000 ($610,000). Together with the principal amount of CAD$6,838,000 ($5,472,000) of Debentures issued on July 12, 2017, the Corporation issued a total aggregate principal amount of CAD$7,600,000 ($6,082,000) of Debentures at a price of CAD$1,000 ($800) per Debenture. On June 25, 2020, the debentureholders approved the extension of the maturity date of the convertible debentures from June 30, 2020 to June 30, 2022 and the conversion price was reduced from CAD$1.35 ($1.08) to CAD$0.50 ($0.40). This extension was accounted for as an extinguishment and the debentures were re-measured at fair value on June 30, 2020. The components of the convertible debentures are as follows: March 31, 2022 December 31, Face value of the convertible debentures $ 4,003 $ 3,977 Transaction costs (75 ) (74 ) Accretion 399 344 Convertible debentures $ 4,327 $ 4,247 The convertible debentures have been recorded as a liability. The accretion expense for the three-month period ended March 31, 2022 amounts to CAD$62,000 ($49,000), compared to CAD$73,000 ($58,000) for the comparative period in 2021. During the three-month period ended March 31, 2022, CAD$40,000 ($32,000) of convertible debentures were converted into 80,000 common shares at the option of the holders, resulting in an increase in additional paid-in capital of $31 thousand. During the three-month period ended March 31, 2021, CAD$240,000 ($191,000) of convertible debentures were converted into 480,000 common shares at the option of the holders, resulting in an increase in additional paid-in capital of $178 thousand. The interest accrued on the convertible debentures for the three-month period ended March 31, 2022 amounts to CAD$110 thousand ($87 thousand) and is recorded in financing and interest expense. The interest on the convertible debentures amounted to CAD$146 thousand ($115 thousand) for the three-month period ended March 31, 2021.

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2022
Convertible Notes [Abstract]
Convertible Notes [Text Block]	8. Convertible Notes On August 5, 2021, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $2.1 million principal amount of 8% convertible notes due July 31, 2025. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.40 per Share. The Company intends to use the proceeds of the Offering for the Montelukast clinical program. In connection with the Offering, the Company paid to an agent a cash commission of approximately $199,525 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 613,000 common shares at a price of $0.40 per Share until August 4, 2023. Management has determined the value of the agents' warrants to be $164,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $268 thousand were recorded against the liability. The accretion expense for the three-month period ended March 31, 2022 amounts to $21,000 (2021: $Nil). The warrants have been recorded as equity. Upon adoption of ASU 606-20, the beneficial conversion feature was reversed on January 1, 2022. The components of the convertible notes are as follows: March 31, 2022 December 31, Face value of the convertible notes $ 2,101 $ 2,101 Transaction costs (403 ) (403 ) Accretion 54 58 Beneficial conversion feature - (411 ) Convertible notes $ 1,752 $ 1,345 The interest on the convertible notes for the three-month period ended March 31, 2022 amounts to $42,000 (2021: $Nil) and is recorded in financing and interest expense. On May 8, 2018, the Company closed its previously announced offering by way of private placement (the "Offering"). In connection with the Offering, the Company issued 320 units (the "Units") at a subscription price of $10,000 per Unit for gross proceeds of $3,200,000. A related party of the Company participated in the Offering and subscribed for an aggregate of two Units. Each Unit is comprised of (i) 7,940 common shares of the Corporation ("Common Shares"), (ii) a $5,000 convertible 6% note (a "Note"), and (iii) 7,690 warrants to purchase common shares of the Corporation ("Warrants"). Each Note bears interest at a rate of 6% (payable quarterly, in arrears, with the first payment being due on September 1, 2018), matured on June 1, 2021 and is convertible into Common Shares at a conversion price of $0.80 per Common Share. Each Warrant entitled its holder to purchase one Common Share at a price of $0.80 per Common Share until June 1, 2021. In connection with the Offering, the Company paid to the Agents a cash commission of approximately $157,800 in the aggregate and issued non-transferable agents' warrants to the Agents, entitling the Agents to purchase 243,275 common shares at a price of $0.80 per share until June 1, 2021. Management has determined the value of the agents' warrants to be $50,000. The proceeds of the Units are attributed to liability and equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872 On May 19, 2021, the noteholders approved the amendment of the terms of the convertible notes. The maturity date of the convertible notes was extended from June 1, 2021 to October 31, 2024, the interest rate of the notes increased from 6% to 8%, and the conversion price was reduced from $0.80 to $0.44. These amendments were accounted for as an extinguishment and the notes were re-measured at fair value on June 1, 2021. This re-measurement resulted in a gain on extinguishment in the amount of $151,000 recognized in finance and interest income. The components of the convertible notes subsequent to the amendments are as follows: March 31, 2022 December 31, Face value of the convertible notes $ 909 $ 909 Transaction costs (29 ) (29 ) Accretion 29 21 Convertible notes $ 909 $ 901 The convertible notes have been recorded as a liability. Total transactions costs in the amount of $29 thousand were recorded against the liability. The accretion expense for the three-month period ended March 31, 2022 amounts to $7,000 (2021: $67,000). The interest on the convertible notes for the three-month period ended March 31, 2022 amounts to $20,000 and is recorded in financing and interest expense (2021: $24,000). On October 15, 2020, the Company announced the closing of an offering by way of private placement to certain investors in the United States of $1.2 million principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. The Company intends to use the proceeds of the Offering for working capital purposes. In connection with the Offering, the Company paid to an agent a cash commission of approximately $85,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 482,000 common shares at a price of $0.18 per Share until October 15, 2022. On October 23, 2020, the Company announced the closing of a second tranche of the Notes to certain investors in the United States of $557 thousand principal amount of 8% convertible notes due October 15, 2024. The Notes will bear interest at a rate of 8% per annum, payable quarterly, and will be convertible into shares of common stock of the Company beginning 6 months after their issuance at a price of $0.18 per Share. In connection with the Offering, the Company paid to an agent a cash commission of approximately $39,000 in the aggregate and issued non-transferable warrants to the agent, entitling the holder to purchase 222,800 common shares at a price of $0.18 per Share until October 15, 2022. Management has determined the value of the agents' warrants to be $44,000. The convertible notes have been recorded as a liability. Total transactions costs in the amount of $268 thousand were recorded against the liability. The accretion expense for the three-month period ended March 31, 2022 amounts to $14,000 (2021: $13,000). The warrants have been recorded as equity. The components of the convertible notes are as follows: March 31, December 31, 2021 Attributed value of net proceeds to convertible notes $ 1,397 $ 1,397 Accretion 80 66 Convertible note 1,477 $ 1,463 The interest on the convertible notes for the three-month period ended March 31, 2022 amounts to $33,000 (2021: $35,000) and is recorded in financing and interest expense.

Capital Stock

Capital Stock	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Capital Stock [Text Block]	9. Capital Stock March 31, 2022 December 31, Authorized - 450,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 154,651,289 (December 31, 2021 - 154,571,289) common shares $ 1 $ 1 On May 11, 2021, the shareholders approved a resolution to amend IntelGenx's Certificate of Incorporation to increase the total number of shares of common stock that IntelGenx is authorized to issue from 200,000,000 shares to 450,000,000 shares. Atai Life Sciences On May 11, 2021, the Company announced that a significant majority of its shareholders had approved the resolution approving the previously announced investment in IntelGenx by atai Life Sciences, pursuant to which atai acquired an approximate 25% interest in IntelGenx. On May 14, 2021, the Company reported that the previously announced $12,346,300 investment in IntelGenx by atai Life Sciences had been completed. As a result of the investment, atai held 25% of the issued and outstanding common stock of IntelGenx. Under the securities and purchase agreement, atai purchased Initial Units composed of 37,300,000 shares of common stock of the Company and 22,380,000 warrants for aggregate gross proceeds of $12,346,300. Each warrant will entitle atai to purchase one share at a price of $0.35 for a period of three years from closing of the initial investment. The proceeds of the transaction are attributed to equity components based on the fair value of each component as follows: Gross proceeds Transaction costs Net proceeds Common stock $ 8,695 $ 297 $ 8,398 Warrants 3,651 125 3,526 $ 12,346 $ 422 $ 11,924 The securities purchase agreement also provides atai with the right to subscribe (in cash, or in certain circumstances, atai equity) for up to 130,000,000 additional units for a period of three years from the closing of the initial investment. Each additional unit will be comprised of (i) one share of common stock and (ii) one half of one warrant. The price for the additional units will be (i) until the date which is 12 months following the closing, $0.331 (subject to certain exceptions), and (ii) following the date which is 12 months following the closing, the lower of (A) a 20% premium to the market price on the date of purchase, and (B) $0.50 if purchased in the second year following closing and $0.75 if purchased in third year following closing. Each additional warrant will entitle atai, for a period of three years from the date of issuance, to purchase one share at the lesser of either (i) a 20% premium to the price of the corresponding additional share, or (ii) the price per share under which shares of the Company are issued under convertible instruments that were outstanding on February 16, 2021, the date on which the parties entered into a non-binding letter of intent to enter into a definitive securities purchase agreement, provided that atai may not exercise additional warrants to purchase more than the lesser of 44,000,000 common shares of the Company, and the number of common shares issued by the Company under outstanding convertibles.

Additional Paid-In Capital

Additional Paid-In Capital	3 Months Ended
	Mar. 31, 2022
Additional Paid in Capital [Abstract]
Additional Paid-In Capital [Text Block]	10. Additional Paid-In Capital Stock options On January 20, 2022, 25,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.34. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $6 thousand. On January 11, 2021, 150,000 options to purchase common stock were granted to an employee under the 2016 Stock Option Plan. The options have an exercise price of $0.27. The options granted vest over a period of 2 years at a rate of 25% every six months and expire 10 years after the grant date. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $25 thousand. No stock options were exercised during the three-month periods ended March 31, 2022 and 2021. Compensation expenses for stock-based compensation of $32 thousand and $31 thousand were recorded during the three-month periods ended March 31, 2022 and 2021, respectively. An amount of $29 thousand expensed in the three-month period ended March 31, 2022 relates to stock options granted to employees and an amount of $3 thousand relates to stock options granted to a consultant. An amount of $31 thousand expensed in the three-month period ended March 31, 2021 relates to stock options granted to employees and an amount of $Nil relates to stock options granted to consultants. As at March 31, 2022, the Company has $120 Warrants No warrants were exercised during the three-month periods ended March 31, 2022 and 2021. Deferred Share Units ("DSUs") On January 1, 2022, 543,480 DSUs have been granted under the DSU Plan, accordingly, an amount of $197 thousand has been recognized in general and administrative expenses. No DSUs were granted during the three-month period ended March 31, 2021. Performance and Restricted Share Units ("PRSUs") No PRSUs were granted during the three-month periods ended March 31, 2022 and 2021.

Revenues

Revenues	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenues [Text Block]	11. Revenues The following table presents our revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues: March 31, 2022 March 31, 2021 Research and development agreements $ 225 $ 126 Product revenue - 160 Royalties on product sales 12 - $ 237 $ 286 The following table presents our revenues disaggregated by timing of recognition: March 31, 2022 March 31, 2021 (in U.S. $ thousands) Product and services transferred at point in time $ 12 $ 160 Products and services transferred over time 225 126 $ 237 $ 286 The following table presents our revenues disaggregated by geography, based on the billing addresses of our customers: March 31, March 31, Europe $ 237 214 Canada - 72 $ 237 $ 286 Remaining performance obligations As at March 31, 2022, the aggregate amount of the transaction price allocated to the remaining performance obligation is $1,803 representing research and development agreements, the majority of which is expected to be recognized in the next twelve months. The Company is also eligible to receive up to $2,559 in research and development milestone payments, approximately 100% of which is expected to be recognized in the next three years; up to $433 in commercial sales milestone payments which are wholly dependent on the marketing efforts of our development partners. In addition, the Company is entitled to receive royalties on potential sales.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases [Text Block]	12. Leases Operating leases Substantially all our operating lease right-of-use assets and operating lease liability represents leases for office space and property to conduct our business. The operating lease expense for the three-month period ended March 31, 2022 included in general and administrative expenses is $69 thousand. The cash outflows from operating leases for the three-month period ended March 31, 2022 was $68 thousand. The weighted average remaining lease term and the weighted average discount rate for operating leases at March 31, 2022 were 3.9 years and 10%, respectively. The following table reconciles the undiscounted cash flows for the operating leases as at March 31, 2022 to the operating lease liabilities recorded on the balance sheet: Operating Leases 2022 208 2023 281 2024 289 2025 289 2026 48 Total undiscounted lease payments 1,115 Less: Interest 259 Present value of lease liabilities $ 856 Current portion of operating lease liability $252 Operating lease liability $604 Finance leases Substantially all our finance lease right-of-use assets and finance lease liability represents leases for laboratory equipment to conduct our business. The cash outflows from finance leases for the three-month period ended March 31, 2022 was $9 thousand. The weighted average remaining lease term and the weighted average discount rate for finance leases at March 31, 2022 were 2.8 years and 6.35%, respectively. The following table reconciles the undiscounted cash flows for the finance leases as at March 31, 2022 to the finance lease liabilities recorded on the balance sheet: Finance Leases 2022 $ 33 2023 43 2024 41 2025 7 Total undiscounted lease payments 124 Less: Interest 12 Present value of lease liabilities $ 112 Current portion of finance lease liability $37 Finance lease liability $75

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	13. Related Party Transactions Included in management salaries are $3 thousand (2021 - $3 thousand) for options granted to the Chief Executive Officer, $3 thousand (2021 - $3 thousand) for options granted to the Chief Financial Officer, $2 thousand (2021 - $7 thousand) for options granted to the Vice President, Operations, $2 thousand (2021 - $2 thousand) for options granted to the Vice-President, Research and Development, $2 thousand (2021 - $2 thousand) for options granted to Vice-President, Business and Corporate Development and $4 thousand (2021 - $4 thousand) for options granted to the Vice-President, Intellectual Property and Legal Affairs under the 2016 Stock Option Plan. Also included in general and administrative expense for the three-month period ended March 31, 2022 are director fees of $67 thousand (2021 - $58 thousand) and DSU expense of $68 thousand (2021: $115 thousand). The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.

Basic and Diluted Loss Per Comm

Basic and Diluted Loss Per Common Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Loss Per Common Share [Text Block]	14. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible debenture and notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies [Text Block]	15. Contingencies The government authorities have assessed the Company with respect to sales taxes claimed on certain expenses between 2017 and 2020, which the government is denying. The sales tax assessments amount to $340,000 (including interest and penalties of $36,000), which was paid to avoid further interest and penalties. The Company disagrees with the government's position and the sales tax assessments are under appeal. In the event the Company is unsuccessful in its appeal, sales taxes expenses would increase by $304,000 and net earnings would decrease by $304,000.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events Abstract
Subsequent Event [Text Block]	16. On May 10, 2022, the shareholders of the Company approved the 2022 Amendment Resolution to amend and restate the 2016 Stock Option Plan. The Board had previously approved the amendment of the 2016 Stock Option Plan to make certain amendments to align the plan with evolving industry practice and shareholder expectations, as well as amendments of a housekeeping nature, which amendments were subject to ratification by Shareholders. As a result of the adoption of the 2022 Stock Option Plan, no additional options will be granted under the 2016 Stock Option Plan and all previously granted options will be governed by the 2022 Stock Option Plan. Similar to the 2016 Stock Option Plan, the 2022 Stock Option Plan permits the granting of options to officers, employees, directors and eligible consultants of the Company. An aggregate number of up to 10% of the Company's issued and outstanding shares (on a non-diluted basis) or 15,465,129 will be issuable under the amended plan less 6,157,389 stock options already granted under previous versions of the Company's Stock Option Plan.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Revenue Recognition [Policy Text Block]	Revenue Recognition The Company may enter into licensing and collaboration agreements for product development, licensing, supply and manufacturing for its product pipeline. The terms of the agreements may include non-refundable signing and licensing fees, milestone payments and royalties on any product sales derived from collaborations. These contracts are analyzed to identify all performance obligations forming part of these contracts. The transaction price of the contract is then determined. The transaction price is allocated between all performance obligations on a residual standalone selling price basis. The stand-alone selling price is estimated based on the comparable market prices, expected cost plus margin and the Company's historical experience. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any sales incentives and amounts collected on behalf of third parties. The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. The following is a description of principal activities - separated by nature - from which the Company generates its revenue. Product revenue The Company recognizes revenue from the sale of its products when the following conditions are met: delivery has occurred; the price is fixed or determinable; the collectability is reasonably assured and persuasive evidence of an arrangement exists Research and Development Revenue Revenues with corporate collaborators are recognized as the performance obligations are satisfied over time, and the related expenditures are incurred pursuant to the terms of the agreement. Licensing and Collaboration Arrangements Licenses are considered to be right-to-use licenses. As such, the Company recognizes the licenses revenues at a point in time, upon granting the licenses. Milestone payments are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, research and other revenues in the period during which the adjustment is recognized. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is significant risk that the Company may not earn all of the milestone payments for each of its contracts. Royalties are typically calculated as a percentage of net sales realized by the Company's licensees of its products (including their sub-licensees), as specifically defined in each agreement. The licensees' sales generally consist of revenues from product sales of the Company's product pipeline and net sales are determined by deducting the following: estimates for chargebacks, rebates, sales incentives and allowances, returns and losses and other customary deductions in each region where the Company has licensees. Revenues arising from royalties are considered variable consideration. As such, the Company estimates variable consideration at the most likely amount to which we expect to be entitled. The estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.
Leasehold Improvements and Equipment [Policy Text Block]	Leasehold Improvements and Equipment Leasehold improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows: On the declining balance method - Laboratory and office equipment Computer equipment On the straight-line method - Leasehold improvements Manufacturing equipment Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Leases [Policy Text Block]	Leases Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. Substantially all of the Company's operating leases are comprised of office space and property leases. The finance leases are comprised of laboratory equipment leases. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured as the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's secured incremental borrowing rate for the same term as the underlying lease. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. The Company has elected not to recognize right-of-use assets and lease liabilities for short-tern leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.
Adoption of accounting policies [Policy Text Block]	Adoption of accounting policies ASU 2020-06-Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity The FASB issued ASU 2020-06,1 which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU 2020-06") to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity's own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity's own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of AASU 2020-06 had a substantial impact on the Company's balance sheet. The August 2021 convertible notes (note 8) contained a beneficial conversion feature. Under the new requirements, the beneficial conversion feature no longer requires to be recognized separately and the convertible notes are treated as a single financial liability. As such, the most significant impact were the reversals of the beneficial conversion feature and the deferred income tax liability. The impact of the adoption of ASU 2020-06 on the balance sheet as at December 31, 2021 was: As reported December 31, 2021 Adoption of ASC 2020-06 Increase Balance January 1, 2022 Convertible notes $ 3,709 $ 388 $ 4,097 Deferred income tax liability 79 (79 ) - Total liabilities 14,034 309 14,343 Additional paid-in capital 63,104 (325 ) 62,779 Accumulated deficit (57,863 ) 23 (57,840 ) Total shareholders' equity 3,871 (309 ) 3,562 Total liabilities and shareholders' equity 17,905 - 17,905

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]	On the declining balance method - Laboratory and office equipment Computer equipment On the straight-line method - Leasehold improvements Manufacturing equipment
Schedule of Accounting Standards Update and Change in Accounting Principle [Table Text Block]	As reported December 31, 2021 Adoption of ASC 2020-06 Increase Balance January 1, 2022 Convertible notes $ 3,709 $ 388 $ 4,097 Deferred income tax liability 79 (79 ) - Total liabilities 14,034 309 14,343 Additional paid-in capital 63,104 (325 ) 62,779 Accumulated deficit (57,863 ) 23 (57,840 ) Total shareholders' equity 3,871 (309 ) 3,562 Total liabilities and shareholders' equity 17,905 - 17,905

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Leasehold Improvements and Equipment [Table Text Block]	March 31, December 31, Accumulated Net Carrying Net Carrying Cost Depreciation Amount Amount Manufacturing equipment $ 4,951 $ 1,602 $ 3,349 $ 3,349 Laboratory and office equipment 1,528 1,131 397 382 Computer equipment 158 118 40 39 Leasehold improvements 3,489 2,112 1,377 1,443 $ 10,126 $ 4,963 $ 5,163 $ 5,213

Loan Payable (Tables)

Loan Payable (Tables)	3 Months Ended
	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Schedule of Term Loan [Table Text Block]	March 31, 2022 $ December 31, 2021 $ Loan payable to atai 5,500 2,500 Total debt 5,500 2,500 Less: current portion - - Total long-term debt 5,500 2,500

Convertible Debentures (Tables)

Convertible Debentures (Tables)	3 Months Ended
	Mar. 31, 2022
Convertible Debt [Abstract]
Schedule of Convertible Debt [Table Text Block]	March 31, 2022 December 31, Face value of the convertible debentures $ 4,003 $ 3,977 Transaction costs (75 ) (74 ) Accretion 399 344 Convertible debentures $ 4,327 $ 4,247

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Instrument [Line Items]
Schedule of Capital Units [Table Text Block]	Gross proceeds Transaction costs Net proceeds Common stock $ 1,627 $ 167 $ 1,460 Convertible notes 1,086 111 975 Warrants 487 50 437 $ 3,200 $ 328 $ 2,872
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Schedule of Components of the Convertible Notes [Table Text Block]	March 31, 2022 December 31, Face value of the convertible notes $ 2,101 $ 2,101 Transaction costs (403 ) (403 ) Accretion 54 58 Beneficial conversion feature - (411 ) Convertible notes $ 1,752 $ 1,345
Amendment To Convertible Note [Member]
Debt Instrument [Line Items]
Schedule of Components of the Convertible Notes [Table Text Block]	March 31, 2022 December 31, Face value of the convertible notes $ 909 $ 909 Transaction costs (29 ) (29 ) Accretion 29 21 Convertible notes $ 909 $ 901
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Schedule of Components of the Convertible Notes [Table Text Block]	March 31, December 31, 2021 Attributed value of net proceeds to convertible notes $ 1,397 $ 1,397 Accretion 80 66 Convertible note 1,477 $ 1,463

Capital Stock (Tables)

Capital Stock (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of Stock by Class [Table Text Block]	March 31, 2022 December 31, Authorized - 450,000,000 common shares of $0.00001 par value 20,000,000 preferred shares of $0.00001 par value Issued - 154,651,289 (December 31, 2021 - 154,571,289) common shares $ 1 $ 1
Schedule of Proceeds of Equity Components [Table Text Block]	Gross proceeds Transaction costs Net proceeds Common stock $ 8,695 $ 297 $ 8,398 Warrants 3,651 125 3,526 $ 12,346 $ 422 $ 11,924

Revenues (Tables)

Revenues (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue [Table Text Block]	March 31, 2022 March 31, 2021 Research and development agreements $ 225 $ 126 Product revenue - 160 Royalties on product sales 12 - $ 237 $ 286
Schedule of Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	March 31, 2022 March 31, 2021 (in U.S. $ thousands) Product and services transferred at point in time $ 12 $ 160 Products and services transferred over time 225 126 $ 237 $ 286
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	March 31, March 31, Europe $ 237 214 Canada - 72 $ 237 $ 286

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of undiscounted cash flows for the operating leases [Table Text Block]	Operating Leases 2022 208 2023 281 2024 289 2025 289 2026 48 Total undiscounted lease payments 1,115 Less: Interest 259 Present value of lease liabilities $ 856
Schedule of operating lease liabilities [Table Text Block]	Current portion of operating lease liability $252 Operating lease liability $604
Schedule of undiscounted cash flows for the finance leases [Table Text Block]	Finance Leases 2022 $ 33 2023 43 2024 41 2025 7 Total undiscounted lease payments 124 Less: Interest 12 Present value of lease liabilities $ 112
Schedule of financing lease liabilities [Table Text Block]	Current portion of finance lease liability $37 Finance lease liability $75

Significant Accounting Polici_4

Significant Accounting Policies - Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details)	3 Months Ended
	Mar. 31, 2022
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage	20.00%
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description	declining balance method
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment, Estimated Useful Live Depreciation Methods Percentage	30.00%
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description	declining balance method
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	straight-line method
Property Plant And Equipment, Estimated Useful Live Depreciation Methods Description	over the lease term
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Depreciation Methods	straight-line method
Manufacturing equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Manufacturing equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

Significant Accounting Polici_5

Significant Accounting Policies - Impact of the Adoption of ASU 2020-06 (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes	$ 4,138	$ 3,709
Deferred income tax liability	0	79
Total liabilities	17,422	14,034
Additional paid-in capital	62,842	63,104
Accumulated deficit	(60,526)	(57,863)
Total shareholders' equity	614	3,871
Total liabilities and shareholders' equity	$ 18,036	17,905
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes		3,709
Deferred income tax liability		79
Total liabilities		14,034
Additional paid-in capital		63,104
Accumulated deficit		(57,863)
Total shareholders' equity		3,871
Total liabilities and shareholders' equity		17,905
Restatement Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes		4,097
Deferred income tax liability		0
Total liabilities		14,343
Additional paid-in capital		62,779
Accumulated deficit		(57,840)
Total shareholders' equity		3,562
Total liabilities and shareholders' equity		17,905
Accounting Standards Update 2020-06 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Convertible notes		388
Deferred income tax liability		(79)
Total liabilities		309
Additional paid-in capital		(325)
Accumulated deficit		23
Total shareholders' equity		(309)
Total liabilities and shareholders' equity		$ 0

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Inventory Disclosure [Abstract]
Raw materials inventory	$ 88	$ 62

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	$ 5,163	$ 5,213
Asset not yet in service [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Net	$ 1,881	$ 1,832

Leasehold improvements and Eq_4

Leasehold improvements and Equipment - Schedule of Leasehold Improvements and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 10,126
Accumulated Depreciation	4,963
Leasehold improvements and equipment, net	5,163	$ 5,213
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	4,951
Accumulated Depreciation	1,602
Leasehold improvements and equipment, net	3,349	3,349
Laboratory and office equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	1,528
Accumulated Depreciation	1,131
Leasehold improvements and equipment, net	397	382
Computer equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	158
Accumulated Depreciation	118
Leasehold improvements and equipment, net	40	39
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	3,489
Accumulated Depreciation	2,112
Leasehold improvements and equipment, net	$ 1,377	$ 1,443

Bank Indebtedness (Narrative) (

Bank Indebtedness (Narrative) (Details) - Mar. 31, 2022 $ in Thousands, $ in Thousands	CAD ($)	USD ($)
Corporate Credit Cards [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 75	$ 60
Corporate Credit Cards 2 [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit		60
Foreign Exchange Contract [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 425	$ 340

Loans Payable (Narrative) (Deta

Loans Payable (Narrative) (Details)	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Sep. 30, 2021USD ($)	May 31, 2021USD ($)	Dec. 31, 2017CAD ($)	Dec. 31, 2017USD ($)	Jul. 12, 2017CAD ($)	Jul. 12, 2017USD ($)
Debt Instrument [Line Items]
Aggregate principal amount						$ 7,600,000	$ 6,082,000	$ 6,838,000	$ 5,472,000
Total debt	$ 5,500,000		$ 2,500,000
Long-term loan	$ 5,500,000		$ 2,500,000
atai Life Sciences [Member] | Term loan facility [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 3,000,000
atai Life Sciences [Member] | Secured Loan [Member]
Debt Instrument [Line Items]
Aggregate principal amount					$ 2,000,000
Additional advance					$ 500,000
Interest rate	8.00%				8.00%
Financing and interest expense	$ 91,000	$ 10,000
Initial amount of loan and additional advances				$ 2,500,000
Long-term loan	$ 2,500,000

Loans Payable - Schedule of com

Loans Payable - Schedule of components of the Company's debt (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Loan payable to atai	$ 5,500	$ 2,500
Total debt	5,500	2,500
Less: current portion	0	0
Long-term loan	$ 5,500	$ 2,500

Convertible Debentures (Narrati

Convertible Debentures (Narrative) (Details)	Aug. 08, 2017CAD ($)	Aug. 08, 2017USD ($)	Jul. 12, 2017CAD ($)$ / sharesshares	Jul. 12, 2017USD ($)	Jun. 25, 2020$ / shares	Jun. 25, 2020$ / shares$ / shares	Mar. 31, 2022CAD ($)shares	Mar. 31, 2022USD ($)shares	Mar. 31, 2021CAD ($)shares	Mar. 31, 2021USD ($)shares	Dec. 31, 2017CAD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2021	Jun. 25, 2020$ / shares	May 08, 2018$ / shares	Dec. 31, 2017USD ($)	Jul. 12, 2017USD ($)$ / sharesshares
Convertible Debentures [Line Items]
Proceeds from Convertible Debt	$ 762,000	$ 610,000	$ 6,838,000	$ 5,472,000
Aggregate principal amount			6,838,000								$ 7,600,000					$ 6,082,000	$ 5,472,000
Proceeds from Convertible Debt, amount per instrument			$ 1,000	$ 800							$ 1,000	$ 800
Debt Instrument, Interest Rate													8.00%
Debt Instrument, Convertible, Conversion Price | (per share)			$ 1.35		$ 1.35	$ 1.35								$ 1.08	$ 0.80		$ 1.08
Debt Instrument, Convertible, Conversion Price, Decrease | (per share)					$ 0.50	$ 0.40
Debt Instrument, Convertible, Number of shares per instrument | shares			740														740
Accretion Expense							$ 62,000	$ 49,000	$ 73,000	$ 58,000
Stock Issued During Period, Value, Conversion of Convertible Securities							40,000	32,000	240,000	191,000
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | $								31,000
Interest on Convertible Debt, Net of Tax							$ 110,000	$ 87,000	$ 146,000	$ 115,000
Common Stock [Member]
Convertible Debentures [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities | shares							80,000	80,000	480,000	480,000
Additional Paid-in Capital [Member]
Convertible Debentures [Line Items]
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | $								$ 31,000		$ 178,000

Convertible Debentures - Schedu

Convertible Debentures - Schedule of Convertible Debentures (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Convertible Debt [Abstract]
Face value of the convertible debentures	$ 4,003	$ 3,977
Transaction costs	(75)	(74)
Accretion	399	344
Convertible Debt	$ 4,327	$ 4,247

Convertible Notes (Narrative) (

Convertible Notes (Narrative) (Details)	Aug. 05, 2021USD ($)$ / sharesshares	Jun. 01, 2021$ / shares	Oct. 23, 2020USD ($)$ / shares	Oct. 15, 2020USD ($)$ / shares	Oct. 15, 2020USD ($)$ / shares	May 08, 2018USD ($)$ / sharesshares	May 19, 2021USD ($)$ / shares	Oct. 23, 2020USD ($)$ / shares	Mar. 31, 2022CAD ($)	Mar. 31, 2022USD ($)	Mar. 31, 2021CAD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)	Jun. 25, 2020$ / shares	Jun. 25, 2020$ / shares	Dec. 31, 2017CAD ($)	Dec. 31, 2017USD ($)	Jul. 12, 2017CAD ($)$ / shares	Jul. 12, 2017USD ($)$ / shares
Debt Instrument [Line Items]
Debt instrument, face amount																$ 7,600,000	$ 6,082,000	$ 6,838,000	$ 5,472,000
Convertible notes, conversion price | (per share)						$ 0.80								$ 1.35	$ 1.08			$ 1.35	$ 1.08
Commission paid to agents						$ 157,800
Warrants issued during period, value						$ 50,000
Accretion expense										$ 91,000		$ 138,000
Stock Issued During Period, Shares, Conversion of Units | shares						320
Subscription Price of Units						$ 10,000
Common stock issued in units | shares						7,940
Stock Issued During Period, Value, Conversion of Units						$ 3,200,000
Stock Issued During Period, Value, Conversion of Convertible Securities									$ 40,000	32,000	$ 240,000	191,000
Sale of Stock, Price Per Share | $ / shares						$ 0.80
Stock Issued During Period, Shares, Issued for Services | shares						243,275
Equity Issuance, Per Share Amount | $ / shares						$ 0.80
Increase in additional paid-in capital upon conversion of convertible notes										31,000
Convertible Debt Securities [Member]
Debt Instrument [Line Items]
Warrants issued during period | shares						7,690
Convertible debt issued in units						$ 5,000
Interest Rate on Convertible Note						6.00%
Convertible notes [Member]
Debt Instrument [Line Items]
Transaction costs										29,000
Accretion expense										7,000		67,000
Financing and interest expense										20,000		24,000
Private Placement [Member] | Warrant [Member]
Debt Instrument [Line Items]
Warrants issued during period, value								$ 44,000
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Transactions costs of convertible notes										403,000			$ 403,000
Accretion expense										21,000		0
Beneficial conversion feature										0			411,000
Financing and interest expense										42,000		0
8% convertible notes due July 31, 2025 [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 2,100,000
Convertible notes percentage	8.00%
Convertible notes, conversion price | $ / shares	$ 0.40
Commission paid to agents	$ 199,525
Warrants issued during period | shares	613,000
Exercise price of warrants issued | $ / shares	$ 0.40
Warrants issued during period, value	$ 164,000
Transactions costs of convertible notes										268,000
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Transactions costs of convertible notes										268,000
Interest on convertible notes										33,000		35,000
8% convertible notes due Oct 15, 2024 [Member] | Private Placement [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 557,000	$ 1,200,000	$ 1,200,000			$ 557,000
Convertible notes percentage			8.00%	8.00%	8.00%			8.00%
Convertible notes, conversion price | $ / shares			$ 0.18	$ 0.18	$ 0.18			$ 0.18
Exercise price of warrants issued | $ / shares			$ 0.18	$ 0.18	$ 0.18			$ 0.18
Warrants issued during period, value					$ 482,000			$ 222,800
Accretion expense										14,000		$ 13,000
Payments of debt issuance costs			$ 39,000	$ 85,000
Amendment To Convertible Note [Member]
Debt Instrument [Line Items]
Convertible notes, conversion price | $ / shares		$ 0.44					$ 0.80
Transactions costs of convertible notes										$ 29,000			$ 29,000
Interest Rate on Convertible Note		8.00%					6.00%
Gain (Loss) on Extinguishment of Debt							$ 151,000,000

Convertible Notes - Schedule of

Convertible Notes - Schedule of Components of the Convertible Notes (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Convertible notes	$ 4,138	$ 3,709
8% convertible notes due July 31, 2025 [Member]
Debt Instrument [Line Items]
Face value of the convertible notes	2,101	2,101
Transaction costs	(403)	(403)
Accretion	54	58
Beneficial conversion feature	0	(411)
Convertible notes	1,752	1,345
Amendment To Convertible Note [Member]
Debt Instrument [Line Items]
Face value of the convertible notes	909	909
Transaction costs	(29)	(29)
Accretion	29	21
Convertible notes	$ 909	$ 901

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Capital Units (Details) - USD ($) $ in Thousands	May 14, 2021	Mar. 31, 2022
Debt Instrument [Line Items]
Gross proceeds	$ 12,346	$ 3,200
Transaction costs	422	328
Net proceeds	11,924	2,872
Convertible notes [Member]
Debt Instrument [Line Items]
Gross proceeds		1,086
Transaction costs		111
Net proceeds		975
Common stock [Member]
Debt Instrument [Line Items]
Gross proceeds	8,695	1,627
Transaction costs	297	167
Net proceeds	8,398	1,460
Warrants [Member]
Debt Instrument [Line Items]
Gross proceeds	3,651	487
Transaction costs	125	50
Net proceeds	$ 3,526	$ 437

Convertible Notes - Schedule _3

Convertible Notes - Schedule of Components of Convertible Notes Subsequent to the Amendments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Convertible notes	$ 4,138	$ 3,709
8% convertible notes due Oct 15, 2024 [Member]
Debt Instrument [Line Items]
Attributed value of net proceeds to convertible notes	1,397	1,397
Accretion	80	66
Convertible notes	$ 1,477	$ 1,463

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Details) $ in Thousands	May 14, 2021USD ($)shares	Mar. 31, 2022shares	Dec. 31, 2021shares	May 14, 2021$ / shares	May 11, 2021shares	May 10, 2021shares
Class of Stock [Line Items]
Common stock, shares authorized		450,000,000	450,000,000		450,000,000	200,000,000
Atai Life Sciences [Member]
Class of Stock [Line Items]
Ownership interest acquired by equity investment					25.00%
Amount of investment | $	$ 12,346,300
Percentage of issued and outstanding common stock	25.00%
Number of shares issued	37,300,000
Number of warrants issued	22,380,000
Proceeds from issuance of common stock and warrants | $	$ 12,346,300
Exercise price of warrants | $ / shares				$ 0.35
Warrants term				3 years
Securities Purchase Agreement [Member] | Atai Life Sciences [Member]
Class of Stock [Line Items]
Maximum rights to subscribe additional units	130,000,000
Right to subscribe additional units, description	Each additional unit will be comprised of (i) one share of common stock and (ii) one half of one warrant. The price for the additional units will be (i) until the date which is 12 months following the closing, $0.331 (subject to certain exceptions), and (ii) following the date which is 12 months following the closing, the lower of (A) a 20% premium to the market price on the date of purchase, and (B) $0.50 if purchased in the second year following closing and $0.75 if purchased in third year following closing. Each additional warrant will entitle atai, for a period of three years from the date of issuance, to purchase one share at the lesser of either (i) a 20% premium to the price of the corresponding additional share, or (ii) the price per share under which shares of the Company are issued under convertible instruments that were outstanding on February 16, 2021
Maximum number of common shares called by warrants that may not be exercised	44,000,000

Capital Stock - Schedule of Sto

Capital Stock - Schedule of Stock by Class (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	May 11, 2021	May 10, 2021
Stockholders' Equity Note [Abstract]
Common stock, shares authorized	450,000,000	450,000,000	450,000,000	200,000,000
Common stock, par value per share	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, shares, issued	154,651,289	154,571,289
Common stock, value, issued	$ 1	$ 1

Capital stock - Schedule of Pro

Capital stock - Schedule of Proceeds of Equity Components (Details) - USD ($) $ in Thousands	May 14, 2021	Mar. 31, 2022
Schedule of Additional Paid In Capital [Line Items]
Gross proceeds	$ 12,346	$ 3,200
Transaction costs	422	328
Net proceeds	11,924	2,872
Common Stock [Member]
Schedule of Additional Paid In Capital [Line Items]
Gross proceeds	8,695	1,627
Transaction costs	297	167
Net proceeds	8,398	1,460
Warrants [Member]
Schedule of Additional Paid In Capital [Line Items]
Gross proceeds	3,651	487
Transaction costs	125	50
Net proceeds	$ 3,526	$ 437

Additional Paid-In Capital (Nar

Additional Paid-In Capital (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 01, 2022	Jan. 11, 2021	Jan. 20, 2022	Mar. 31, 2022	Mar. 31, 2021
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation				$ 32	$ 31
Employee [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation				29
2016 Stock Option Plan [Member] | Stock options [Member]
Schedule of Additional Paid In Capital [Line Items]
Number of shares granted		150,000	25,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.27	$ 0.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term		2 years	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years	10 years
Stock Granted, Value, Share-based Compensation, Gross		$ 25	$ 6
Stock options granted to consultant [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation				3	31
Unrecognized stock-based compensation [Member]
Schedule of Additional Paid In Capital [Line Items]
Stock based compensation				$ 120	$ 146
Deferred Share Units [Member]
Schedule of Additional Paid In Capital [Line Items]
Deferred share units grants in period	543,480
General and administrative expenses	$ 197

Revenues (Narrative) (Details)

Revenues (Narrative) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Revenue from Contract with Customer [Abstract]
Transaction price allocated to the remaining performance obligation	$ 1,803
Research and development milestone payments	$ 2,559
Percentages of recognized in next three year	100.00%
Commercial sales milestone payments	$ 433

Revenues - Schedule of Revenue

Revenues - Schedule of Revenue Disaggregated by Revenue Source (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 237	$ 286
Research and development agreements [Member]
Disaggregation of Revenue [Line Items]
Revenue	225	126
Product revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue	0	160
Royalties on product sales [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 12	$ 0

Revenues - Schedule of Revenu_2

Revenues - Schedule of Revenue Disaggregated by Timing of Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 237	$ 286
Product and services transferred at point in time [Member]
Disaggregation of Revenue [Line Items]
Revenue	12	160
Products and services transferred over time [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 225	$ 126

Revenues - Schedule of Revenu_3

Revenues - Schedule of Revenue Disaggregated by Geography, Based on the Billing Addresses of our customers (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 237	$ 286
Europe [Member]
Disaggregation of Revenue [Line Items]
Revenue	237	214
Canada [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 72

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Operating lease expense	$ 69
Operating lease payments	$ 68
Weighted average remaining lease term	3 years 10 months 24 days
Weighted average discount rate for operating leases	10.00%
Cash outflows from finance leases	$ 9	$ 6
Finance lease weighted average remaining lease term	2 years 9 months 18 days
Weighted average discount rate for finance leases	6.35%

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022	$ 208
2023	281
2024	289
2025	289
2026	48
Total undiscounted lease payments	1,115
Less: Interest	259
Present value of lease liabilities	$ 856

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Current portion of operating lease liability	$ 252	$ 249
Operating lease liability	$ 604	$ 642

Leases - Schedule of Finance Le

Leases - Schedule of Finance Leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Leases [Abstract]
2022	$ 33
2023	43
2024	41
2025	7
Total undiscounted lease payments	124
Less: Interest	12
Present value of lease liabilities	$ 112

Leases - Schedule of Financial

Leases - Schedule of Financial Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Current portion of finance lease liability	$ 37	$ 36
Finance lease liability	$ 75	$ 84

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Options granted to the Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 3	$ 3
Options granted to the Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	3	3
Options granted to the Vice President, Operations [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	2	7
Options granted to the Vice-President, Research and Development [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	2	2
Options granted to Vice-President, Business and Corporate Development [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	2	2
Options granted to the Vice-President, Intellectual Property and Legal Affairs [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	4	4
Director fees [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	67	58
Deferred share units [Member]
Related Party Transaction [Line Items]
Salaries, Wages and Officers' Compensation	$ 68	$ 115

Contingencies (Narratives) (Det

Contingencies (Narratives) (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Sales tax assessments amount	$ 340,000
Sales tax assessments interest and penalties	36,000
Amount of sales taxes expenses increase	304,000
Amount of net earnings decrease	$ 304,000

Subsequent Events (Narratives)

Subsequent Events (Narratives) (Details) - Subsequent Event [Member] - 2022 Stock Option Plan [Member]	May 10, 2022shares
Subsequent Event [Line Items]
Percentage Of Shares Issuable Under Stock Option Plan	10.00%
Shares Issuable Under Stock Option Plan	15,465,129
Number of Shares Granted Under Stock Option Plan	6,157,389